Application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma

A urolithin and allergy technology, applied in the field of compound pharmaceutical use, can solve problems such as undiscovered applications, and achieve the protection of cells from oxidative stress, alleviation of lung eosinophil infiltration, and effective ROS inhibition. Effect

Pending Publication Date: 2022-07-12
SUN YAT SEN UNIV
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In related technologies, urolithin A is often used as a potential neuroprotective agent, promotes the balance of intestinal flora, regulates estrogen secretion, improves diabetes, improves atherosclerosis, and inhibits the proliferation of prostate cancer cells, but has not Discovery of its use in allergic airway disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma
  • Application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma
  • Application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0057] In order to make the invention purpose, technical solutions and technical effects of the present invention clearer, the present invention will be further described in detail below with reference to the specific embodiments. It should be understood that the specific embodiments described in this specification are only for explaining the present invention, rather than for limiting the present invention.

[0058] The experimental materials and reagents used, unless otherwise specified, are conventional consumables and reagents that can be obtained from commercial sources.

[0059] experiment material

[0060] Test drug:

[0061] Dexamethasone (Sigma, USA) was dissolved in DMSO and diluted with PBS solution to make a solution.

[0062] Ellagic acid (Sigma, USA) was dissolved in DMSO and diluted with PBS solution to make a suspension.

[0063] Urolithin A (Sigma, USA) was dissolved in DMSO and diluted with PBS solution to make a suspension.

[0064] Ovalbumin (OVA) was p...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of urolithin A in prevention and treatment of allergic rhinitis and allergic asthma, and the urolithin A is used for treating allergic airway diseases by adjusting lung tissue TXNIP / NLRP3 pathway related proteins. The inventor finds that the urolithin A can significantly improve multiple inflammatory indexes of mice with allergic airway diseases, and compared with ellagic acid, the urolithin A has the effects of improving the nose scratching frequency of the mice in a disease model group, reducing the levels of IL-5, IL-4 and IL-18 in BALF, and improving the inflammatory index of the mice with allergic airway diseases. The traditional Chinese medicine composition has better effects on relieving lung eosinophilic granulocyte infiltration and goblet cell hyperplasia, reducing pathological scores of bronchial and perivascular inflammatory cell infiltration degrees, increasing the level of anti-oxidation factors GSH of lung tissues, reducing TXNIP, ASC and IL-1beta protein expression of the lung tissues and reducing the proportion of NLRP3 and TXNIP positive cells.

Description

technical field [0001] The invention belongs to the field of compound pharmaceutical use, in particular to the application of urolithin A in preventing and treating allergic rhinitis and allergic asthma. Background technique [0002] With the advancement of urbanization, environmental pollution has become more and more serious, and the incidence of allergic rhinitis (AR) and asthma has increased significantly in the past two decades, affecting 10%-20% of the global population, and as high as 80%. Allergic asthma accounts for % of childhood asthma and more than 50% of adult asthma cases. AR and allergic asthma often co-exist, both belong to allergic airway diseases, and are usually characterized by increased infiltration of various inflammatory cells, elevation of various inflammatory factors and abnormal airway remodeling, accompanied by asthma, chest tightness and coughing and other symptoms. Its pathogenesis is complex and has not yet been fully studied. Among them, the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/37A61P11/00A61P37/08A61P11/06A61P11/02
CPCA61K31/37A61P11/00A61P37/08A61P11/06A61P11/02
Inventor 杨燕郭兴悦李琴申云琴
Owner SUN YAT SEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products